Other languages Merck & Co., Inc.

Equities

MRK

US58933Y1055

Real-time Estimate Cboe BZX Other stock markets 10:40:24 2023-12-07 am EST			5-day change	1st Jan Change
103.92 ^USD	-1.62%		+1.50%	-6.25%

04:30pm	Biden Administration Launches Measures to Cut Health Care Costs; Proposes Use of 'March-In Rights' for Drugs	MT
03:18pm	President Biden Announces Health Care Measure to Lower Costs, Promote Competition, 'March-In' Drug Patents on Govt-Funded Research	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biden Administration Launches Measures to Cut Health Care Costs; Proposes Use of 'March-In Rights' for Drugs	10:30am
Merck : arrêt d'une étude clinique dans le cancer du poumon	08:24am
Merck Discontinues Phase 3 KEYLYNK-008 Trial for Not Reaching Primary Endpoints	07:37am
Merck's lung cancer drug combo fails to meet trial goal	06:09am
European Equities Close Higher in Wednesday Trading; Eurozone Retail Trade Rises	Dec. 06
Merck Collaborates with Acceleration Consortium on Open-Sourcing AI-Driven Experimentation Planner Bayesian Back End	Dec. 06
Las bolsas europeas suben apoyadas por la minería; el DAX alemán, en máximos históricos	Dec. 06
European shares gain on miners' boost, German DAX at fresh record high	Dec. 06
AVIS D'ANALYSTES DU JOUR : LVMH, Alstom, Carefour, ALD, JCDecaux, Ocado, Nel...	Dec. 06
Hibercell, Inc. Announces Clinical Collaboration with Merck to Evaluate Hibercell, Inc. in Combination with Welireg in a Phase 1B Study of Patients with Clear Cell Renal Cell Carcinoma	Dec. 05
Le père fouettard tente une contre-attaque	Dec. 05
Bolsa de Madrid: El hombre del saco intenta un contraataque	Dec. 05
Merck : revue prioritaire dans le cancer de la vessie	Dec. 01
Lauterbach will Pharma-Produktion verstärkt nach Deutschland holen	Dec. 01
Merck Says FDA Grants Priority Review to Application for Keytruda Plus Padcev for Urothelial Cancer Treatment	Nov. 30
FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer	Nov. 30
Acclinate Collaborates with Merck to Increase Clinical Trial Diversity	Nov. 30
Doubleverify Holdings Insider Sold Shares Worth $56,765,625, According to a Recent SEC Filing	Nov. 29
Merck & Co., Inc. Announces Management Changes, Effective on December 4, 2023	Nov. 28
Merck Declares Dividend for the First Quarter of 2024, Payable on January 8, 2024	Nov. 28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies

Other languages Merck & Co., Inc.

Equities

MRK

US58933Y1055

Other languages

Filters